EBR Systems, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EBR Systems, Inc.
The global market for implantable pacemaker products is expected to reach $5.3bn by 2023, a CAGR of 5.1% from 2017, driven by the rising aging population and growing burden of heart disease.
HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data
Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.
Only three leadless pacemakers have been CE marked to date, as revealed following the publication of recent UK guidelines on how to evaluate such products.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced April-May 2015.
- Implantable Devices
- Surgical Equipment & Devices